Medidata Launches Sensor Cloud
Medidata has announced the launch of Sensor Cloud, a platform for managing a broad range of sensor and digital health technology data during the clinical trial process. Sensor Cloud integrates with Medidata Rave Clinical Cloud and supports continuous patient data collection from both Medidata and third-party medical-grade sensors.
Sensor Cloud provides the ability to:
- Enable insights through proprietary analytics including digital biomarker discovery
- Possibly lower costs and enable greater operational efficiency by making it easier for patients to share data and stay enrolled in trials
- Standardize data from ingestion through delivery via a common data model
- Possibly reduce site and patient burden by cutting down on-site visits, time, and travel through a more flexible engagement model
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
